The total number of breast cancer incident
cases in the nine major markets (9MM) — the US, France, Germany, Italy, Spain,
UK, Japan, urban China and Brazil — is expected to increase by 44% over the
next decade, from 0.90 million in 2012 to 1.29 million by 2022.
The latest report states that the number of
five-year prevalent cases will also grow by 44%, climbing from 3.7 million in
2012 to 5.39 million by 2022. Out of the 9MM, the US and urban China had the
highest number of five-year prevalent cases in 2012, with 1.15 million and
898,406 cases, respectively.
Samantha Lee, Epidemiologist, says: “The
forecast growth in breast cancer incidence is partly due to rising cases of
obesity, growing detection through screening programs, and changes in
reproductive patterns and the use of postmenopausal hormone replacement
therapy.”
According to the World Health Organization,
increased breast cancer survival has contributed greatly to the prevalence of
the disease, and there is a large amount of evidence showing that breast cancer
mammographic screening is effective in reducing the disease mortality by at
least 20% in women aged 50 years and older.
Lee says: “Prevention measures taken to
improve breast cancer survival in parts of the world where organized nationwide
mammography screening has only been made available in recent years, such as
Brazil and China, will boost survival rates and impact the disease incidence and
prevalence in those countries.”
Nonetheless, epidemiologists expect the
impact of screening in these markets to be limited in the short term. This is
due to the lack of sufficient resources and infrastructure needed to support
the downstream healthcare needs associated with screening, such as additional
diagnostic tests and treatment.
Inquire
about this report: http://www.marketresearchreports.com/globaldata/epicast-report-breast-cancer-epidemiology-forecast-2022
Find
all Healthcare report at: http://www.marketresearchreports.com/healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.